IONIS-FB-LRx is under clinical development by F. Hoffmann-La Roche and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect IONIS-FB-LRx’s likelihood of approval (LoA) and phase transition for Geographic Atrophy took place on 20 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their IONIS-FB-LRx Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

IONIS-FB-LRx overview

IONIS-FB-LRx is under development for the treatment of geographic atrophy associated dry age-related macular disease and complement-mediated diseases including primary immunoglobulin A (IgA) nephropathy. It is a ligand conjugated antisense oligonucleotide (LICA) targeting complement factor b. It is administered through subcutaneous route.

F. Hoffmann-La Roche overview

F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.

Quick View IONIS-FB-LRx LOA Data

Report Segments
  • Innovator
Drug Name
  • IONIS-FB-LRx
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Genito Urinary System And Sex Hormones
  • Ophthalmology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.